Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 20, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Targeting the Sigma-1/Nmda Receptor Complex to Ameliorate Cognitive Deficits and Negative Symptoms in Schizophrenia

View Full Paper
Ask AI
Bookmark
Share

Authors

ŁĆŁukasz ĆmokJDJulia DobrowolskaJCJustyna Chudy

Discussion

Loading...

Member takes

Overview

A narrative review analyzes the role of sigma-1 receptor agonists in improving cognitive and negative symptoms in schizophrenia, suggesting new therapeutic avenues.

Key Points

  • This study explores how sigma-1 receptor dysfunction relates to NMDA receptor hypofunction and its implications for schizophrenia treatment.
  • Conducted a narrative review of literature from PubMed, focusing on 2006 to 2026 publications, including older works for key insights.
  • Incorporated findings from European Brain Council reports.
  • Evidence shows sigma-1 receptor stabilizes the transport of NMDA receptors to the cell membrane.
  • Pharmacological stimulation of sigma-1 receptors enhances synaptic plasticity and alleviates cellular stress.
  • Improvements noted in memory, cognitive flexibility, and social interactions after targeting the sigma-1/NMDA complex.

Cite This Study

Ćmok et al. (2026) studied this question.

synapsesocial.com/papers/69e5c22d03c2939914028969https://doi.org/10.31435/ijitss.1(49).2026.5596
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NMDA Receptor Dysfunction and Cognitive Impairment in Schizophrenia: Mechanisms, Evidence and Therapeutic Potential2025
  2. 2Intracellular Crosstalk Between NMDA and Sigma-1 Receptors: A Novel Mechanistic Insight Relevant to Neuropsychiatric Pharmacotherapy2026
  3. 3Targeting endoplasmic reticulum stress and protein misfolding in schizophrenia: the emerging promise of sigma-1 receptor agonists2025
  4. 4Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways2024 · 5 citations
  5. 5Selective mGlu1 Receptor Activation Restores Cortical Inhibitory Tone and Improves Cognitive Performance in a Subchronic Phencyclidine NMDA Hypofunction Model2026